Hepion Secures $400K via Private Placement at $0.05/Share with Warrants
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals raised $400,000 in a new private placement of 8 million shares and 8 million warrants at $0.05 per share, with warrants exercisable at $0.06 for five years.
Key Events · Financing and Capital Events · CTRVP
-
New $400K Private Placement
Sold 8,000,000 shares and 8,000,000 warrants at $0.05 per share for gross proceeds of $400,000.
-
Warrant Terms
Warrants exercisable at $0.06 per share for five years from issuance, adding potential future dilution.
-
Going Concern Context
Follows the August 13, 2026 10-Q going concern warning and a $3.06 million placement on August 4, 2026 at the same $0.05 price.
-
Closing Conditions
Agreements contain customary closing conditions; the offering is not yet closed as of the filing date.
Analysis · CTRVP · Life Sciences
On August 25, 2026, Hepion Pharmaceuticals entered into a new securities purchase agreement, selling 8 million shares and 8 million warrants at $0.05 per share for $400,000 in gross proceeds. The warrants are exercisable at $0.06 per share for five years. This follows a $3.06 million placement at the same $0.05 price on August 4, 2026, and comes amid a going concern warning disclosed in the August 13, 2026 10-Q. The new capital extends the company's runway but adds dilution and potential future dilution from the warrants.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.